HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
Authors
Keywords
Viral replication, HIV, Antiretroviral therapy, Macaque, Viral persistence and latency, Viral load, HIV infections, SIV
Journal
PLoS Pathogens
Volume 11, Issue 7, Pages e1005000
Publisher
Public Library of Science (PLoS)
Online
2015-07-03
DOI
10.1371/journal.ppat.1005000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time-to-infection by Plasmodium falciparum is largely determined by random factors
- (2015) Mykola Pinkevych et al. BMC Medicine
- Post-treatment control of HIV infection
- (2015) Jessica M. Conway et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation
- (2014) Timothy J. Henrich et al. ANNALS OF INTERNAL MEDICINE
- HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
- (2014) N. M. Archin et al. JOURNAL OF INFECTIOUS DISEASES
- Towards a cure for HIV—are we making progress?
- (2014) Sharon R Lewin et al. LANCET
- Persistence by proliferation?
- (2014) D. Margolis et al. SCIENCE
- Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
- (2014) Julian H. Elliott et al. PLoS Pathogens
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
- (2014) Thomas A Rasmussen et al. Lancet HIV
- Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy
- (2013) ANNALS OF INTERNAL MEDICINE
- Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure
- (2013) Ya-Chi Ho et al. CELL
- BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
- (2013) Daniela Boehm et al. CELL CYCLE
- A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
- (2013) A. M. Spivak et al. CLINICAL INFECTIOUS DISEASES
- Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant
- (2013) Deborah Persaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
- (2013) Thomas Rasmussen et al. Human Vaccines & Immunotherapeutics
- Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
- (2013) Susanne Eriksson et al. PLoS Pathogens
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
- (2012) N. M. Archin et al. NATURE
- HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics
- (2012) Rutao Luo et al. PLoS One
- Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection
- (2012) N. M. Archin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Standing Genetic Variation and the Evolution of Drug Resistance in HIV
- (2012) Pleuni Simone Pennings PLoS Computational Biology
- Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions
- (2011) John E. Pearson et al. PLoS Computational Biology
- A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy
- (2009) J. B. Dinoso et al. JOURNAL OF VIROLOGY
- Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy
- (2009) Libin Rong et al. PLoS Computational Biology
- Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
- (2008) Nancy M Archin et al. AIDS
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
- (2008) S. Palmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HIV rebounds from latently infected cells, rather than from continuing low-level replication
- (2008) B. Joos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started